Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study | Zendy

Hitoshi Kumagai | Zendy; Toshiya Ebata | Zendy; Kenji Takamori | Zendy; Taro Muramatsu | Zendy; Hidetomo Nakamoto | Zendy; Hiromichi Suzuki | Zendy

Open Access

Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study

Author(s) -

Hitoshi Kumagai,

Toshiya Ebata,

Kenji Takamori,

Taro Muramatsu,

Hidetomo Nakamoto,

Hiromichi Suzuki

Publication year - 2009

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfp588

Subject(s) - medicine , placebo , visual analogue scale , anesthesia , agonist , clinical endpoint , adverse effect , placebo controlled study , randomized controlled trial , gastroenterology , double blind , receptor , pathology , alternative medicine

Pruritus in haemodialysis patients is an intractable disease and substantially impairs their quality of life. Based on the results of our earlier clinical study, we hypothesized that the micro-(mu) opioid system is itch-inducible, whereas the kappa (kappa) system is itch-suppressive.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research